Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy
of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck
squamous cell carcinoma after the failure or intolerance of immuno-oncology or
immuno-oncology combined with chemotherapy.